文献速递产科母胎医学

支持考虑产前糖皮质激素的实践建议发布后22周早产儿产前糖皮质激素使用情况

Antenatal corticosteroid administration among infants born at 22 weeks' gestation after a practice advisory endorsing its consideration.
PubMed 文献 · Am J Obstet Gynecol MFM · 2025-06-22

本研究基于美国2017-2020年与2022-2023年全国生命统计系统数据,回顾性分析实践建议发布前后22周早产儿产前糖皮质激素使用变化。结果显示22周活产儿使用率从48%(178/368)升至61%(216/356)(P=.001),多因素分析中22周用药比值增高65%(P=.001),而24-25周无显著变化(P=.061)。

要点

  • 2021年美国妇产科医师学会实践建议发布后,22周早产儿产前糖皮质激素使用率从48%升至61%。
  • 多因素分析显示22周早产儿用药比值增高65%(P=.001),24-25周无显著变化(P=.061)。
  • 23周早产儿用药率无显著变化(P=.385),敏感性分析亦无显著关联(P=.710)。

核心结论

  • 美国妇产科医师学会关于22周早产考虑产前糖皮质激素的建议与22周早产儿用药增加相关,24-25周无显著变化。

研究设计与样本

  • 回顾性二次分析,数据来自美国疾病控制与预防中心国家生命统计系统2017-2020年与2022-2023年数据。
  • 纳入符合排除标准后共11,203例22-25周活产儿,主要暴露为指南实施后(2022-2023年)与实施前(2017-2020年)的出生年份。
  • 采用卡方检验和秩和检验比较指南实施前后的孕周,多因素回归采用双重差分模型分析22周与24-25周产前糖皮质激素使用,另以23周活产儿进行敏感性分析。

主要发现

  • 双变量分析:22周活产儿产前糖皮质激素使用率从指南实施前的48%(178/368)升至实施后的61%(216/356)(P=.001)。
  • 双变量分析:23周用药率无变化(P=.385),24-25周仅轻度从63%升至66%(P=.033)。
  • 多因素分析:22周用药比值增高65%(P=.001),24-25周无显著变化(P=.061)。
  • 敏感性分析:22周结果相似(P=.001),23周无显著关联(P=.710)。

临床怎么用

  • 原文未据此给出针对临床实践的具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In response to an accumulation of evidence supporting antenatal steroid administration at 22 weeks of gestation with planned neonatal resuscitation, the American College of Obstetricians and Gynecologists, alongside the Society for Maternal-Fetal Medicine, published a clinical practice advisory recommending consideration of antenatal steroids at 22 weeks of gestation in September 2021. OBJECTIVE: This study aimed to determine whether the 2021 American College of Obstetricians and Gynecologists practice advisory was associated with an increase in the use of antenatal corticosteroids among infants born at 22 weeks of gestation. STUDY DESIGN: This retrospective, secondary analysis used data from the United States Centers for Disease Control and Prevention's National Vital Statistics System from 2017 to 2023. The primary outcome was antenatal steroid use as recorded on the birth certificate, and our main exposure was the birth year that was dichotomized as after (2022-2023) vs before (2017-2020) practice guideline implementation. The chi-square and rank-sum tests were used to compare gestational age before and after the implementation of the guideline, respectively. A multivariate regression using a difference-in-difference specification model was used to determine antenatal steroid use among births at 22 and 24 to 25 weeks of gestation, and a separate multivariate model was included using live births at 23 weeks of gestation for sensitivity analysis. RESULTS: After applying our exclusion criteria, a total of 11,203 live births in the United States at 22 to 25 weeks of gestation between 2017-2020 and 2022-2023 were available for analysis. Our bivariate analysis indicated an increased use of antenatal steroids in live births at 22 weeks of gestation from 48% (178/368) before to 61% (216/356) after the American College of Obstetricians and Gynecologists guideline implementation (P=.001). However, steroid administration did not change at 23 weeks of gestation (P=.385), with only a slight increase from 63% to 66% at 24 to 25 weeks of gestation (P=.033) in our bivariate analysis. Our multivariate analysis found similar patterns, with 65% higher odds of steroid use in births at 22 weeks of gestation (P=.001), with no significant change in births at 24 to 25 weeks of gestation (P=.061). Similar results were found in our sensitivity analysis of births at 22 weeks of gestation (P=.001), but no significant association was identified for births at 23 weeks of gestation (P=.710). CONCLUSION: The recommendation by the American College of Obstetricians and Gynecologists to consider antenatal corticosteroid administration in preterm deliveries at 22 weeks of gestation has led to an increase in this clinical practice. This significant association highlights the value and influence of clinical practice guidelines among clinicians.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Fryar C, Liu T, Bates N, et al. Antenatal corticosteroid administration among infants born at 22 weeks' gestation after a practice advisory endorsing its consideration. Am J Obstet Gynecol MFM. 2025. PMID: 40555340. doi:10.1016/j.ajogmf.2025.101728

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。